NPM1 Mutation Cancer Clinical Trials

A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

147 sites for NCT04293562

BCR-ABL1 Fusion, +48 more biomarkers

Acute Myeloid Leukemia

allogeneic hematopoietic stem cell transplantation, +12 more drugs

cellular therapy, +4 more types

Gemcitabine and Cisplatin Without Cystectomy for Patients With Muscle Invasive Bladder Urothelial Cancer and Select Genetic Alterations

259 sites for NCT03609216

ARID1A Loss, +122 more biomarkers

Bladder Urothelial Carcinoma

chemoradiotherapy, +6 more drugs

chemotherapy, +3 more types

Study to Improve OS in 18 to 60 Year-old Patients, Comparing Daunorubicin Versus High Dose Idarubicin Induction Regimens, High Dose Versus Intermediate Dose Cytarabine Consolidation Regimens, and Standard Versus MMF Prophylaxis of GvHD in Allografted Patients in First CR

48 sites for NCT02416388

BCR-ABL1 Fusion, +24 more biomarkers

Acute Myeloid Leukemia

cyclosporine, +5 more drugs

chemotherapy, +1 more type

Dociparstat (DSTAT) in Combination With Standard Chemotherapy for the Treatment of Acute Myeloid Leukemia (AML) (DASH AML)

14 sites for NCT04571645

ASXL1 Loss, +27 more biomarkers

Acute Myeloid Leukemia

chemotherapy, +1 more drug

chemotherapy, +1 more type

A Study to Assess the Efficacy and Safety of Entospletinib in Combination With Intensive Induction and Consolidation Chemotherapy in Adults With Newly Diagnosed Nucleophosmin 1-mutated Acute Myeloid Leukemia

3 sites for NCT05020665

NPM1 Mutation

Acute Myeloid Leukemia

cytarabine, +3 more drugs

chemotherapy, +1 more type

A Modular Multi-Basket Trial to Improve Personalized Medicine in Cancer Patients (Basket of Baskets)

6 sites for NCT03767075

ATM Loss, +94 more biomarkers

Malignant Solid Tumor

atezolizumab

immunotherapy

Study of Biomarker-Based Treatment of Acute Myeloid Leukemia